111, Inc. (YI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

111, Inc. (YI) Healthcare & Pipeline Overview

111, Inc. (YI) is an integrated online and offline healthcare platform in China, providing pharmaceuticals, wellness products, and healthcare services. Operating through B2B and B2C segments, the company distinguishes itself through its comprehensive supply chain integration and online marketplace, serving pharmacies, pharmaceutical companies, and consumers.

What Is the Investment Thesis for YI?

111, Inc. presents a unique investment opportunity within China's rapidly evolving healthcare market. The company's integrated online and offline platform caters to both businesses and consumers, creating multiple revenue streams. With a market capitalization of $30.1M, the company is positioned to capitalize on the increasing demand for healthcare products and services in China. Key growth catalysts include expanding its online marketplace and further integrating its supply chain. However, the company's negative profit margin of -0.4% and the competitive landscape pose significant risks. The company's beta of 0.70 suggests lower volatility compared to the overall market. Investors should monitor the company's ability to improve profitability and navigate regulatory challenges.

Based on FMP financials and quantitative analysis

YI Key Highlights

Operates an integrated online and offline healthcare platform in China, providing access to a broad range of pharmaceutical and wellness products.

• B2B segment focuses on supplying products and services to pharmacies, pharmaceutical companies, and distributors, creating a diversified revenue stream.
• B2C segment offers direct sales to consumers through online retail and offline pharmacies, enhancing market reach.
• Operates an online marketplace facilitating transactions between third-party sellers and pharmacies, expanding product offerings and revenue opportunities.
• Gross margin of 5.8% indicates potential for improvement through supply chain optimization and pricing strategies.

Who Are YI's Competitors?

YI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are YI's Key Strengths?

Integrated online and offline platform.

• Comprehensive product offerings.
• Strong supply chain integration.
• Established brand name in China.

What Are YI's Weaknesses?

Negative profit margin.

• Limited geographic presence outside of major cities.
• Reliance on third-party sellers for marketplace revenue.
• Exposure to regulatory changes in China.

What Could Drive YI Stock Higher?

Expansion of the online marketplace by attracting more third-party sellers and increasing product offerings.

• Further integration of the supply chain to improve efficiency and reduce costs.
• Potential strategic partnerships with pharmaceutical companies to gain access to exclusive products and marketing support.
• Geographic expansion within China by opening new retail pharmacies and expanding online reach.

What Are the Key Risks for YI?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Intense competition from other online pharmacies and distributors in China.
• Regulatory changes affecting the pharmaceutical industry in China.
• Economic slowdown in China impacting consumer spending on healthcare products.
• Fluctuations in currency exchange rates affecting the value of the ADR.

What Are the Growth Opportunities for YI?

• Expansion of Online Marketplace: 111, Inc. can significantly expand its online marketplace by attracting more third-party sellers and increasing the range of products offered. The online marketplace model allows for scalability and diversification of revenue streams. The market for online pharmaceutical sales in China is projected to reach $50 billion by 2028, presenting a substantial growth opportunity for 111, Inc.
• Further Integration of Supply Chain: Integrating its supply chain can improve efficiency, reduce costs, and enhance the company's competitive position. By streamlining procurement, logistics, and warehousing, 111, Inc. can improve its gross margin and offer more competitive pricing. Investing in advanced supply chain technologies and building strategic partnerships with suppliers can drive this growth.
• Expansion of Value-Added Services: 111, Inc. can expand its value-added services, such as online consultations and electronic prescription services, to attract more customers and generate additional revenue. The market for online healthcare services in China is growing rapidly, driven by increasing demand for convenient and accessible healthcare solutions. By offering a comprehensive suite of services, 111, Inc. can differentiate itself from competitors.
• Strategic Partnerships with Pharmaceutical Companies: Forming strategic partnerships with pharmaceutical companies can provide 111, Inc. with access to exclusive products and marketing support. These partnerships can also help the company expand its product offerings and reach new customer segments. Collaborating with leading pharmaceutical companies can enhance 111, Inc.'s credibility and market position.
• Geographic Expansion within China: 111, Inc. can expand its geographic presence within China by opening new retail pharmacies and expanding its online reach to underserved regions. The Chinese healthcare market is vast and diverse, with significant opportunities for growth in Tier 2 and Tier 3 cities. By targeting these markets, 111, Inc. can increase its customer base and revenue.

What Are YI's Competitive Advantages?

• Integrated Platform: Combines online and offline channels to reach a broad customer base.
• Supply Chain Integration: Streamlines procurement, logistics, and warehousing to improve efficiency.
• Online Marketplace: Provides a platform for third-party sellers to reach pharmacies, expanding product offerings.
• Value-Added Services: Offers online consultations and electronic prescription services to attract and retain customers.

What Does YI Do?

Founded in 2010 and headquartered in Shanghai, China, 111, Inc. (YI), formerly known as New Peak Group, has evolved into a comprehensive healthcare platform. The company operates through two primary segments: B2B and B2C. Its B2C operations involve selling medical and wellness products directly to consumers through online retail and its own retail pharmacies under the Yi Hao Pharmacy brand. The B2B segment focuses on supplying products and services to pharmacies, pharmaceutical companies, and distributors. 111, Inc. offers a wide array of products, including prescription and over-the-counter drugs, nutritional supplements, contact lenses, medical supplies, personal care products, and baby products. Beyond product sales, 111, Inc. provides value-added services such as online consultations and electronic prescription services. The company also operates an online marketplace, enabling third-party sellers to reach pharmacies directly. Additionally, 111, Inc. offers supply chain integration, data services, warehousing, logistics, procurement, research and development, and IT support. As of December 31, 2021, 111, Inc. operated 14 offline retail pharmacies across several Chinese provinces.

What Products and Services Does YI Offer?

• Operates an integrated online and offline healthcare platform in China.
• Sells medical and wellness products through online retail and wholesale channels.
• Provides value-added services such as online consultations and electronic prescriptions.
• Operates retail pharmacies under the Yi Hao Pharmacy brand.
• Offers an online marketplace for third-party sellers to reach pharmacies.
• Provides supply chain integration and data services to pharmacies and pharmaceutical companies.

How Does YI Make Money?

• B2C: Sells medical and wellness products directly to consumers through online retail and retail pharmacies.
• B2B: Supplies products and services to pharmacies, pharmaceutical companies, and distributors.
• Marketplace: Generates revenue from transaction fees on its online marketplace.
• Value-Added Services: Charges fees for online consultations and electronic prescription services.

What Industry Does YI Operate In?

111, Inc. operates within China's dynamic healthcare market, which is experiencing rapid growth driven by increasing healthcare spending and an aging population. The market is characterized by a mix of online and offline players, with a growing emphasis on digital healthcare solutions. 111, Inc. competes with other online pharmacies and traditional pharmaceutical distributors. The company's integrated platform and focus on supply chain integration provide a competitive edge. The Chinese government's support for digital healthcare initiatives also presents opportunities for growth.

Who Are YI's Key Customers?

• Consumers seeking medical and wellness products.
• Pharmacies requiring pharmaceutical supplies and services.
• Pharmaceutical companies seeking distribution channels.
• Distributors requiring supply chain integration and data services.

Company Profile

111, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Junling Liu. YI has traded publicly since 2018.

111, Inc. Financial Trajectory

111, Inc. (YI) reported $352.7M in revenue for Q1 FY2026, a decline of 15.1% compared to the prior quarter. The company recorded a net loss of $5.5M, with diluted EPS of $-0.63. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, YI averaged $-0.36 in diluted EPS.

How 111, Inc. Is Valued

111, Inc. carries a market capitalization of $30.1M, placing it in the micro-cap category. Relative to its peer group, YI's quantitative score of 39/100 is below the peer average of 53/100.

Return on equity for 111, Inc. stands at 13.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -45.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -37.6%, the inverse of the P/E and a quick read on earnings relative to price.

111, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 37.95 places it in the safe zone, indicating low near-term bankruptcy risk.

Over the past six months, 111, Inc. insiders filed 24 SEC Form 4 transactions — 12 sales and 12 purchases. On net that is roughly 3.5M shares acquired (about $141K) — insiders putting money in tends to read as conviction.

YI Financials

YI Latest News

YI Analyst Consensus

YI MoonshotScore

YI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources